R&D
Rooted in distinctive platform technology based on strong medicinal chemistry expertise, LCB is a global biotechnology company dedicated to drug discovery and development
Core Technology
Our Technology
Next Generation ADC platform
LCB’s novel ADC platform technologies overcome the existing limitations of ADCs by imparting a trinity of improved properties, (1) site-specific stable bioconjugation (2) cancer selective linker activation and (3) cancer-selective activation of potent payload, all of which in a significantly broader Therapeutic Window.
Conventional ADCs: Random conjugation
LCB's next-generation ADCs: Site-specific conjugation
Antibodies
Unmet Needs
Antibody modification alters physicochemical properties of the antibody, including PK profile and binding affinity
- PK Profile
- Binding Affinity
Solutions
Minimizes modification of antibody structure for ADC
Conjugation
Unmet Needs
Mixtures
- Generates significant impurities
Solutions
Single substance
- Produces a highly pure single substance
Linkers
Unmet Needs
Blood stability
- Reduces drug efficacy and safety through separation of linkers in blood
Toxin Release Rate
- Needs to improve the separation rate of toxins in cancer cells
Solutions
Stable linkers in blood
Efficient drug release by specific enzymes in cancer cells
Toxin
Unmet Needs
Needs high anticancer effect
Loss of efficacy due to tolerance in cancer cells
Solutions
New MOA-based toxins
Conjugation-Linkers Platform
Site-specific conjugation enabling
production of homogeneous ADC
production of homogeneous ADC
Plasma stable linker enabling
cancer specific toxin release
cancer specific toxin release
Excellent PK profile through proprietary
conjugation and linker chemistry
conjugation and linker chemistry
Extra CaaX seq
at Carboxyl-terminus of light chains
C : cysteine
a : aliphatic amino acid
X : one of a variety of amino acids
C : cysteine
a : aliphatic amino acid
X : one of a variety of amino acids
Prenylation
Recognition of CaaX and adding a substrate (a functionalized prenyl substrate) to Cys of CaaX through a covalent bond (alkylsulfide formation) by prenyl transferase (Farnesyl transferase)
Conjugation
Chemical versatility of conjugation including click chemistry or oxime ligation between isoprenoid and linker functionalities
Toxin Platform (PBD Prodrug)
Tumor-selectively activated PBD
prodrug technology
prodrug technology
Inactive, if released prematurely
in blood circulation
in blood circulation
Wider Therapeutic Index through
Superior efficacy & Reduced toxicity
Superior efficacy & Reduced toxicity